Document is current

Article History

Received: 30 July 2025

Accepted: 17 September 2025

First Online: 29 September 2025

Declarations

:

: No animal studies were carried out by the authors for this article.

: No human studies were carried out by the authors for this article.

: Drs. G. Nakhlé and J. LeLorier have received grants from the Montreal Heart Institute for this project.Dr. J-C.Tardif reports grant from Amarin, grant from AstraZeneca, grant from Ceapro, grants, personal fees and minor equity interest from Dalcor Pharmaceuticals, grant from Esperion, grant from Ionis, grant from Merck, grants from Novartis, fees from Pendopharm, and grant and fees from Pfizer, outside the submitted work; in addition, Dr. Tardif has a patent “Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent” pending, a patent “Methods for using low dose colchicine after myocardial infarction” pending, a patent “Methods of treating a coronavirus infection using colchicine” pending, and a patent “Early administration of low-dose colchicine after myocardial infarction" pending; Dr. Tardif has waived his rights in the colchicine patents and do not stand to gain financially.Dr. A. Dubois has no relevant financial or non-financial interests to disclose.